
Amaxa® Cell Line Nucleofector® Kit V

For T/C-28a2


SV40- immortalized human juvenile costal chondrocytes polygonal / fibroblast like adherent cells

Example for Nucleofection® of T/C-28a2





T/C-28a2 cells were transfected using the Cell Line Nucleofector® Kit V, program X-001 (for Nucleofector® II) or X-01 (for Nucleofector® I) and 2 µg of pmaxGFP®. 24 hours post Nucleofection® the cells were analyzed by light (A) and fluorescence microscopy (B). Data kindly provided by Jochen Haag, University of Leipzig



Average transfection efficiencies and viability of T/C-28a2 cells. Cells were transfected with program X-001 [for Nucleofector® II]/X-01 [for Nucleofector®I] and 2 µg of pmaxGFP® Vector. 24 hours post Nucleofection®, the cells were analyzed by flow cytometry. Cell viability was analyzed 24 hours post Nucleofection® by using the CellTiterGlo assay [Promega]. Data kindly provided by Jochen Haag, University of Leipzig.

Product Description

Cat. No.	VCA-1003
Size (Reactions)	25
Cell Line Nucleofector Solution V	2.25 ml (2.05 ml + 10% overfill)
Supplement	0.5 ml (0.45 ml + 10% overfill)
pmaxGFP® Vector (0.5 μg/μl in 10 mM Tris pH 8.0)	30 µg
Certified cuvettes	25
Plastic pipettes	25

Storage and stability

Store Nucleofector® Solution, Supplement and pmaxGFP® Vector at 4°C. For long-term storage, pmaxGFP® Vector is ideally stored at -20°C. The expiration date is printed on the solution box. Once the Nucleofector® Supplement is added to the Nucleofector® Solution, it is stable for three months at 4°C.

Optimized Protocol for T/C-28a2

Required Material

Note Please make sure that the entire supplement is added to the Nucleofector® Solution.

- Nucleofector® Device
- Supplemented Nucleofector® Solution at room temperature
- Supplied certified cuvettes
- Supplied plastic pipettes
- Supplied pmaxGFP® Vector
- Substrate of interest, highly purified, preferably by using endotoxin free kits; A260: A280 ratio should be at least 1.8
- 6-well culture dish or culture system of your choice
- For trypsinization: 0.5 mg/ml Trypsin and 0.2 mg/ml EDTA in PBS and supplemented culture media or PBS/0.5% BSA
- Appropriate volume of culture media at 37°C and 5% $\rm CO_2$ (DMEM/Ham's F-12 supplemented with 10% FCS)
- Appropriate number of cells (1x10⁶ cells per sample)

1. Pre Nucleofection®

Cell culture recommendations

- 1.1 Passage cells every 4 6 days, split ratio 1:10
- 1.2 Seed 1x10⁶ cells/ml per 10 cm dish 1 day before Nucleofection® to achieve the 80% confluence recommended for Nucleofection®

Note Do not let the cells overgrow.

Trypsinization

- 1.3 Remove media from the cultured cells and wash cells once with PBS; use at least same volume of PBS as culture media
- 1.4 For harvesting, incubate the cells 10 minutes at 37°C with recommended volume of indicated trypsinization reagent (please see required material)
- 1.5 Stop trypsinization reaction with DMEM/F12 supplemented with 10% FCS

Optimized Protocol for T/C-28a2

2. Nucleofection®

One Nucleofection® Sample contains

1 x 106 cells

 $1-2~\mu g$ plasmid DNA (in $1-5~\mu l$ H $_20$ or TE) or $2~\mu g$ pmaxGFP® Vector or 30~nM-300~nM siRNA [3-30~pmol/sample]

100 µl Nucleofector® Solution

- 2.1 Please make sure that the entire supplement is added to the Nucleofector® Solution
- 2.2 Prepare 6-well plates by filling appropriate number of wells with 1.5 ml of supplemented culture media and pre-incubate/equilibrate plates in a humidified $37^{\circ}\text{C/5}\%$ CO₂ incubator
- 2.3 Harvest the cells by trypsinization (please see 1.4 1.6)
- 2.4 Count an aliquot of the trypsinized cells and determine cell density
- 2.5 Centrifuge the required number of cells (1 x 10⁶ cells per sample) at 300xg for 10 minutes at room temperature
- 2.6 Resuspend the cell pellet carefully in 100 µl room temperature Nucleofector® Solution per sample
- 2.7 Combine 100 μ l of cell suspension with $1 2 \mu g$ DNA or $2 \mu g$ pmaxGFP® Vector or appropriate amount of siRNA (30 nM 300 nM or 3 30 pmol/sample) or other substrates
- 2.8 Transfer cell/DNA suspension into certified cuvette; sample must cover the bottom of the cuvette without air bubbles
- 2.9 Select the appropriate Nucleofector® Program X-001
- 2.10 Insert the cuvette with cell/DNA suspension into the Nucleofector® Cuvette Holder and apply the selected program
- 2.11 Take the cuvette out of the holder once the program is finished
- 2.12 Add 500 µl of the pre-equilibrated culture media to the cuvette and gently transfer the sample immediately into the 6-well plate (final volume 1.5 ml media per well/sample). Use the supplied pipettes and avoid repeated pipetting of the sample

3. Post Nucleofection®

3.1 Incubate the cells in a humidified 37° C/5% CO_2 incubator until analysis. Gene expression or down regulation, respectively, is often detectable after only 4-8 hours

Additional Information

For an up-to-date list of all Nucleofector® References, please refer to: www.lonza.com/nucleofection-citations

For more technical assistance, contact our Scientific Support Team:

 USA/Canada
 Europe and Rest of World

 Phone:
 800 521 0390 (toll-free)
 Phone: +49 221 99199 400

 Fax:
 301 845 8338
 Fax: +49 221 99199 499

References

1. Mary B. Goldring et al. (1994) J. Clin. Invest. 94:2307-2316

Lonza Cologne AG 50829 Cologne, Germany

 $Please \ note that \ the \ Amaxa^{@}\ Nucleo fector ^{@}\ Technology\ is\ not\ intended\ to\ be\ used\ for\ diagnostic\ purposes\ or\ for\ testing\ or\ treatment\ in\ humans.$

The Nucleofector® Technology, comprising Nucleofection® Process, Nucleofector® Device, Nucleofector® Solutions, Nucleofector® 96-well Shuttle® System and 96-well Nucleocuvette® plates and modules is covered by patent and/or patent-pending rights owned by Lonza Cologne AG.

Amaxa, Nucleofector, Nucleofection and maxGFP are either registered trademarks or trademarks of the Lonza Cologne AG in Germany and/or U.S. and/or other countries.

 $Other \, product \, and \, company \, names \, mentioned \, herein \, are \, the \, trademarks \, of \, their \, respective \, owners.$

This kit contains a proprietary nucleic acid coding for a proprietary copepod fluorescent protein intended to be used as a positive control with this Lonza product only. Any use of the proprietary nucleic acid or protein other than as a positive control with this Lonza product is strictly prohibited. USE IN ANY OTHER APPLICATION REQUIRES A LICENSE FROM EVROGEN. To obtain such a license, please contact Evrogen at license@evrogen.com.

The CMV promoter is covered under U.S. Patents 5,168,062 and 5,385,839 and its use is permitted for research purposes only. Any other use of the CMV promoter requires a license from the University of Iowa Research Foundation, 214 Technology Innovation Center, Iowa City, IA 52242.

The use of this product in conjunction with materials or methods of third parties may require a license by a third party. User shall be fully responsible for determining whether and from which third party it requires such license and for the obtainment of such license.

No statement is intended or should be construed as a recommendation to infringe any existing patent.

@ Copyright 2009, Lonza Cologne AG. All rights reserved DCV-1054 06/09